Lassau Nathalie, Chami Linda, Chebil Mohamed, Benatsou Baya, Bidault Sophie, Girard Elizabeth, Abboud Ghassen, Roche Alain
Imaging Department, Institut Gustave Roussy, Villejuif, France.
Discov Med. 2011 Jan;11(56):18-24.
Dynamic contrast-enhanced ultrasonography (DCE-US) is a current functional imaging technique enabling a quantitative assessment of tumor perfusion using raw linear data. DCE-US allows calculating several parameters as slope of wash-in or area under the curve representing, respectively, blood flow or blood volume. Decrease of vascularization can easily be detected in responders after 1 or 2 weeks of anti-angiogenic treatment for gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), and hepatocellular carcinoma (HCC) and is correlated with progression-free survival and overall survival in RCC or HCC. DCE-US is supported by the French National Cancer Institute (INCa), which is currently studying the technique in metastatic breast cancer, melanoma, colon cancer, gastrointestinal stromal tumors and renal cell carcinoma, as well as in primary hepatocellular carcinoma, to establish the optimal perfusion parameters and timing for quantitative anticancer efficacy assessments. Currently 479 patients are included in 19 centers and the preliminary results on 400 patients with 1096 DCE-US demonstrated that the area under the curve (AUC) quantified at 1 month could be a robust parameter to predict response at 6 months.
动态对比增强超声检查（DCE-US）是一种当前的功能成像技术，能够使用原始线性数据对肿瘤灌注进行定量评估。DCE-US允许计算几个参数，如分别代表血流或血容量的流入斜率或曲线下面积。在对胃肠道间质瘤（GIST）、肾细胞癌（RCC）和肝细胞癌（HCC）进行1或2周的抗血管生成治疗后，很容易在反应者中检测到血管化的降低，并且这与RCC或HCC的无进展生存期和总生存期相关。DCE-US得到了法国国家癌症研究所（INCa）的支持，该研究所目前正在转移性乳腺癌、黑色素瘤、结肠癌、胃肠道间质瘤和肾细胞癌以及原发性肝细胞癌中研究该技术，以确定用于定量抗癌疗效评估的最佳灌注参数和时机。目前，19个中心纳入了479名患者，对400名患者进行1096次DCE-US的初步结果表明，1个月时量化的曲线下面积（AUC）可能是预测6个月时反应的一个可靠参数。
